Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), executed a series of transactions on July 8, 2026.
• These transactions involved the exercise of 9,500 stock options at a price of $135.42 per share, resulting in the acquisition of 9,500 shares of common stock.
• Concurrently, a total of 10,000 shares of common stock were sold in multiple transactions at weighted average prices ranging from $547.98 to $560.88.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt's direct beneficial ownership of common stock is reported as 40,513 shares, with additional shares held indirectly through trusts and by a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions conducted under a pre-established compliance plan, rather than indicating new strategic developments or significant financial performance changes.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating adherence to established compliance procedures for insider stock sales.
• The exercise of options at $135.42 and sale of shares at significantly higher prices ($547.98 - $560.88) suggests a substantial gain for the reporting person.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market, despite being part of a pre-planned strategy.

Risks

• The 10b5-1 plan is subject to expiration on December 31, 2026, or upon the exercise of all remaining options, introducing a time-bound element to future transactions.
• The plan's continuation is also contingent on the exercise of 1,734,410 stock options, which expire on March 15, 2027.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. The plan covers the exercise of options and subsequent sale of shares.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO of a biotechnology company like United Therapeutics is a common strategy to manage personal stock sales in a compliant manner, especially given the volatility often associated with the sector.

Stakeholder Impact

• Shareholders may interpret the sale of shares by the CEO, even under a 10b5-1 plan, with varying degrees of concern or neutrality, depending on market sentiment and the company's performance.
• Employees may observe executive compensation and stock transaction activities as indicators of company health and leadership confidence.

Next Steps

• Continuation of the 10b5-1 trading plan until its termination date or option exercise limit is reached.
• Potential future filings on Form 4 to report further transactions under the plan.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, 10b5-1 Plan, United Therapeutics, UTHR, Martine Rothblatt, Common Stock, Beneficial Ownership